Cannabinoid Safety and Regulation Act: New FDA Rules and Impaired Driving Prevention
This Act establishes a comprehensive regulatory framework for cannabinoid products under the Food and Drug Administration (FDA), including the creation of a new Center for Cannabinoid Products. Citizens will benefit from enhanced safety standards, strict labeling requirements, and a ban on sales to individuals under 21. Furthermore, the legislation allocates funds for research and programs aimed at preventing cannabis-impaired driving, directly impacting road safety.
Key points
Product Safety: The FDA will establish the Center for Cannabinoid Products to oversee manufacturing, testing, and labeling, ensuring products are not adulterated or misbranded.
Consumer Protection: Mandatory, clear labels must disclose THC content, allergens, and risks for special populations (e.g., pregnant women), alongside a prohibition on sales to individuals under 21.
Flavor Ban: Electronic cannabinoid product delivery systems (vaping) are prohibited from containing added artificial or natural flavors (except for terpenes within specified limits).
Road Safety: The Act funds research into cannabis-impaired driving and establishes grant programs for states to enhance prevention and enforcement efforts against driving under the influence of cannabis.
Registration and Penalties: Manufacturers and importers must register with the FDA and comply with good manufacturing practices, with high civil penalties imposed for violations.
Status:
Expired
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.